The study by Wang W. et al. [41] showed that hesperidin may inhibit the expression and activity of COX-2 in liver tissue, and, therefore, it had a therapeutic effect on NAFLD rats. This evidence concerns the gene PTGS2 and metabolic dysfunction-associated steatotic liver disease.